Companies › Dynavax Technologies
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Vaccines, Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rF1V-1018 Recombinant F1 antigen and V antigen fusion vaccine | – | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | Jan 2027 |
| Z-1018 Herpes Zoster vaccine | – | Phase 1 | Shingles | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07207408 | rF1V-1018 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | Infectious disease | Jan 2027 |
| NCT06569823 | Z-1018 | Phase 1 | Shingles | Vaccines | Jun 2027 |
No annotated target.
–
Cellid Guangzhou Patronus Biotech Aribio Lab Vaxcyte Inventprise
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.